Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation

Select host restriction factors are associated with HIV persistence during antiretroviral therapy

(2015) Mohamed Abdel-Mohsen et al.   AIDS

Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients

(2015) Adam M. Spivak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

Rapid Viral Rebound After 4 Years of Suppressive Therapy in a Seronegative HIV-1 Infected Infant Treated From Birth

(2015) Karina M. Butler et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

(2015) Guochun Jiang et al.   PLoS Pathogens

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

(2015) Julian H Elliott et al.   Lancet HIV

Galectin-9 Is Rapidly Released During Acute HIV-1 Infection and Remains Sustained at High Levels Despite Viral Suppression Even in Elite Controllers

(2014) Ravi Tandon et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

(2014) Timothy J. Henrich et al.   ANNALS OF INTERNAL MEDICINE

Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells

(2014) Chuan Wu et al.   IMMUNITY

Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions

(2014) K. Nagahara et al.   JOURNAL OF IMMUNOLOGY

Decreased HIV Type 1 Transcription in CCR5-Δ32 Heterozygotes During Suppressive Antiretroviral Therapy

(2014) Charlene Wang et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

The Histone Deacetylase Inhibitor Vorinostat (SAHA) Increases the Susceptibility of Uninfected CD4+ T Cells to HIV by Increasing the Kinetics and Efficiency of Postentry Viral Events

(2014) M. B. Lucera et al.   JOURNAL OF VIROLOGY

Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies

(2014) C. Vandergeeten et al.   JOURNAL OF VIROLOGY

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes

(2014) Richard Brad Jones et al.   PLoS Pathogens

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

(2014) Datsen George Wei et al.   PLoS Pathogens

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy

(2013) A. M. Spivak et al.   CLINICAL INFECTIOUS DISEASES

Calcium/Calcineurin Synergizes with Prostratin to Promote NF-κB Dependent Activation of Latent HIV

(2013) Jonathan K. Chan et al.   PLoS One

Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection

(2013) Stephanie Jost et al.   Retrovirology

Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease

(2013) Yuko Kurose et al.   BMC Nephrology

Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient

(2013) Steven A. Yukl et al.   PLoS Pathogens

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

(2013) Asier Sáez-Cirión et al.   PLoS Pathogens

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

(2012) M. K. Gleason et al.   BLOOD

Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection

(2012) S. Elahi et al.   BLOOD

Lower-Sensitivity and Avidity Modifications of the Vitros Anti-HIV 1+2 Assay for Detection of Recent HIV Infections and Incidence Estimation

(2012) S. M. Keating et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

(2012) Brian A. DeChristopher et al.   Nature Chemistry

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

(2012) Cole Trapnell et al.   Nature Protocols

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation

(2012) Zichong Li et al.   NUCLEIC ACIDS RESEARCH

Role of retroviral restriction factors in the interferon- -mediated suppression of HIV-1 in vivo

(2012) S. K. Pillai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reactivation of Latent HIV-1 by Inhibition of BRD4

(2012) Jian Zhu et al.   Cell Reports

CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21

(2011) Huabiao Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry

(2011) S. Bi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency

(2010) Moises Perez et al.   CURRENT HIV RESEARCH

In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus

(2010) Leonard Chávez et al.   METHODS

Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia

(2010) J. Kuroda et al.   MOLECULAR CANCER RESEARCH

Galectin-9 trafficking regulates apical-basal polarity in Madin–Darby canine kidney epithelial cells

(2010) Rashmi Mishra et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8+ T Cell Response

(2010) Sharvan Sehrawat et al.   PLoS Pathogens

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection

(2009) Sophie Reuse et al.   PLoS One

Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis

(2008) Masako Seki et al.   CLINICAL IMMUNOLOGY

Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1

(2008) Nozomu Nishi et al.   GLYCOBIOLOGY

Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices

(2008) A. Nobumoto et al.   GLYCOBIOLOGY

Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death Pathways

(2008) Shuguang Bi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of Tim-3–Galectin-9 pathway improves survival of fully allogeneic skin grafts

(2008) Feng Wang et al.   TRANSPLANT IMMUNOLOGY